Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies

This publication has 13 references indexed in Scilit:

• In vivo glyco‐engineered antibody with improved lytic potential produced by an innovative non‐mammalian expression system
  Biotechnology Journal, 2007
• High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
  Molecular Immunology, 2005
• Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of FcγRIIIa Functional Polymorphism
  Clinical Cancer Research, 2004
• Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma
  Cancer Research, 2004
• Fucose Depletion from Human IgG1 Oligosaccharide Enhances Binding Enthalpy and Association Rate Between IgG1 and FcγRIIIa
  Journal of Molecular Biology, 2004
• The Structure of a Human Type III Fcγ Receptor in Complex with Fc
  Journal of Biological Chemistry, 2001
• Different types of FC γ -receptors are involved in anti-Lewis Y antibody induced effector functions in vitro
  British Journal of Cancer, 2000
• IgG‐Fc‐mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation
  Immunological Reviews, 1998
• Crystallographic structure of an intact IgG1 monoclonal antibody 1 1Edited by I. A. Wilson
  Journal of Molecular Biology, 1998
• Clinical significance of IgG Fc receptors and FcγR-directed immunotherapies
  Immunology Today, 1997